Skip to main content

Table 7 Wilcoxon sign-rank test was used to test the difference between pre-PP1M and Post-PP1M. Comparison of Direct Costs, Indirect Costs and Total Costs Before and After Transition to PP1M

From: A health economics study of long-acting injectable once-monthly paliperidone palmitate in schizophrenia: a one-year mirror-image study in China

  Direct costs Indirect costs Total costs
pre-PP1M (¥) 17,457±17,414 15,967±10,128 33,095±21,984
Post-PP1M (¥) 23,030±8648 10,279±11,878 33,309±15,254
Difference 31.92 -35.62% 0.64%
P < 0.01 < 0.01 0.25